Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GI-102 Alone or With Pembrolizumab in Recurrent High-Grade Glioma
NCT07301268Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Aug 2026
- Primary completion
- Sep 2029
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of GI-101A in glioblastoma (GBM), astrocytoma, Gliosarcoma (GS), sponsored by Mayo Clinic. Started Aug 2026; status: recruiting.
02
Drugs
GI-101A
03
Conditions
glioblastoma (GBM)astrocytomaGliosarcoma (GS)
Beyond the preview
Go deeper on NCT07301268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07301268.